BIOMERICA ANNOUNCES THE START OF CLINICAL TRIALS ON TESTS FOR PREDICTING DIABETES
BIOMERICA ANNOUNCES THE START OF CLINICAL TRIALS
ON TESTS FOR PREDICTING DIABETES
NEWPORT BEACH, Calif., Nov. 18 /PRNewswire/ -- Biomerica Inc. (NASDAQ: BMRA), has announced that it will begin clinical trials on two blood test kits for identifying individuals who are likely to develop diabetes as early as seven years before the onset of the disease. The tests measure antibodies produced by the human body against insulin and the pancreatic islet cells which produce insulin. During the clinical phase, the kits will be marketed for research only.
These unique kits will enable Biomerica to participate in the diabetic market totaling $22 billion per year.
Diabetes affects 7 million Americans and another million individuals have the molecular indicators of the impending disease in their blood for months, years, or perhaps even decades before clinical symptoms appear. The ability to detect this pre-diabetic state through Biomerica's kits may permit physicians to take preventive measures before the disease becomes incurable and causes serious injury to the eyes, kidneys, blood vessels and nervous system.
Biomerica is a biomedical company engaged in the development, manufacturing and sales of advanced diagnostic products for heart attack, predisposition of diabetes, allergy, occult blood, certain cancers, and other clinical tests. In addition, Biomerica has an interest in a transdermal drug delivery operation as well as an orthodontic manufacturing firm.
/CONTACT: Joseph H. Irani, president or Zackary S. Irani, 714-645-2111, of Biomerica/
(BMRA) CO: Biomerica ST: California IN: MTC SU: AL-EH -- LA003 -- 1247 11/18/91 09:04 EST